Psychedelic Stock Review Initiates Coverage on Ehave Inc.
MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics...
Small Pharma's DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers
Dataset generated from Phase I enables the selection of the optimal dose...
Every successful drug was once in Phase I.
"In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the...
Ehave's Covid Passport provides small businesses a tool to verify Covid-19 vaccination, and a suite of products to improve both the mental and overall health of individuals.
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for methamphetamine use disorder and...
Mental Health and Wellness Incubator Set to Launch Four Initiatives.Trading at Year Low.Launching Clinical Trial With Brain Scientific to Monitor Ketamine Efficacy.Launching Clinical Trial With Mycotopia Therapies and PsyBioMed.Launching...
